Sometimes you have to admit it. Things didn’t work out the way you wanted and it’s not great.
That’s what Tim Collins has to say in his space on RealMoney: “Timing is everything.”
Recently Collins wrote that his position in Draganfly DFLYF seemed ready to pay off and pay off quite well. A week later, he hadn’t exactly reversed his position. But he wasn't as happy about Draganfly as he was originally.
“I misjudged the big money demand for both Draganfly and CurrencyWorks (CWRK). I definitely overestimated where I thought money could be raised, how it would be raised, and how it would be structured. I link the two because they have some ownership commonalities.”
TheStreet RecommendsPRESS RELEASESAGILE ROBOTS Announces The Completion Of Series C Financing Led By SoftBank Vision Fund 217 minutes agoPRESS RELEASESSea Limited Announces Pricing Of Offerings Of ADSs And Convertible Notes20 minutes agoPRESS RELEASESState Street Corporation Prices Common Stock Offering24 minutes ago
“In terms of timing, trying to be a small cap and uplist with a cap raise (essentially an IPO of sorts), I can't think of a worse time to try and do such a thing in years. OK, so maybe March 2020 was worse … the small cap market has lacked demand for weeks now, and Robinhood's (HOOD) – Get Robinhood Report IPO flopped. Add in the U.S. halting new Chinese IPOs and some illogical trading breaking small caps both on the upside and downside lately and it's an institutional buyer's market.”
Best Small Cap Stocks To Watch Right Now: Abbott Laboratories(ABT)
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
FINANCIAL INFORMATION RELATING TO INDUSTRY SEGMENTS, GEOGRAPHIC AREAS, AND CLASSES OF SIMILAR PRODUCTS
Incorporated herein by reference is Note 15 entitled “Segment and Geographic Area Information” of the Notes to Consolidated Financial Statements included under Item 8, “Financial Statements and Supplementary Data.”
NARRATIVE DESCRIPTION OF BUSINESS
Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
Prior to January 1, 2013, Abbott had five reportable segments, which included Proprietary Pharmaceutical Products. Advisors’ Opinion:
- [By ]
The company also has a Sentiment Grade of B, which means it has shown consistent growth and price performance. For instance, the stock has a beta of 0.63, which indicates it is not very volatile. See the complete POWR Ratings analysis for Abbott Laboratories (ABT) here.
- [By Will Ashworth]
I commented that in the nearly nine years since the company was spun-off by Abbott Laboratories (NYSE:ABT), it’s grown revenues 149% to $45.8 billion in 2020.
- [By ]
IHI's top positions among its 60-something holdings at present include insertable heart monitor maker Abbott Laboratories (ABT), specialty diagnostics firm Thermo Fisher Scientific (TMO) and cellular analysis specialist Danaher (DHR). The healthcare fund is admittedly pretty focused on this trio, with 36% of all assets in the three positions, but they are entrenched and stable ways to play the sector without worrying about drug patent expirations.
Best Small Cap Stocks To Watch Right Now: EV Energy Partners, L.P.(EVEP)
EV Energy Partners, L.P. engages in the acquisition, development, and production of oil and natural gas properties in the United States. Its properties are located in the Barnett Shale; the Appalachian Basin; the San Juan Basin; Michigan; Central Texas; the MidContinent areas in Oklahoma, Texas, Arkansas, Kansas, and Louisiana; the Monroe Field in Northern Louisiana; and the Permian Basin. As of December 31, 2015, the company had estimated net proved reserves of 22.0 million barrels of oil; 747.0 billion cubic feet of natural gas; and 36.3 million barrels of natural gas liquids. EV Energy GP, L.P. serves as the general partner of EV Energy Partners, L.P. EV Energy Partners, L.P. was founded in 2006 and is based in Houston, Texas.
Advisors’ Opinion:
- [By ]
Exelon Corp. (NYSE: EXC) is up more than 16.5% over the past six months and 3.5% over the past month alone. It’s less than $1 away from 52-week highs, and it’s a serious contender to revisit all-time highs above $80. Exelon management will put 3.06% in your pocket every quarter while you wait, too.
- [By ]
Some 87% of the fund's assets are invested in plain ol' utility stocks – companies such as Duke Energy (DUK), Dominion Energy (D) and Exelon (EXC). And although they do indeed have ties to uranium – all three utilities produce electricity from a collective 27 nuclear plants – their businesses simply aren't positioned to benefit from spikes in uranium prices the same way that uranium miners and several other related companies are.
- [By Ethan Ryder]
Shares of Exelon Co. (NYSE:EXC) have received a consensus recommendation of “Buy” from the eighteen research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $47.00.
- [By Motley Fool Transcribers]
Exelon Corp (NYSE:EXC)Q4 2018 Earnings Conference CallFeb. 08, 2019, 10:00 a.m. ET
Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:Operator
